Eli Lilly’s Mounjaro added to China’s national health insurance for diabetes

Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for the Long Term. Eli Lilly and Company ...

Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatment

By Andrew Silver SHANGHAI, Dec 8 (Reuters) - Eli Lilly's popular drug Mounjaro will be added to China's state-run health ...

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...

Eli Lilly Further Cements Itself As The King Of Weight Loss

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Investing.com South Africa

Moody’s affirms Eli Lilly’s Aa3 rating, outlook revised to positive

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

EU Committee Backs Extending Use of Lilly's Diabetes Drug for Children Aged 10 and Above

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ...

Eli Lilly just delivered fantastic news to investors

Eli Lilly shares have climbed in the double digits this year.

Eli Lilly's next-gen obesity drug shows biggest weight loss yet in clinical trial

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...